Taysha Gene Therapies
TSHA
109 hedge funds and large institutions have $402M invested in Taysha Gene Therapies in 2024 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 29 increasing their positions, 27 reducing their positions, and 14 closing their positions.
157% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 14
75% more capital invested
Capital invested by funds: $230M → $402M (+$172M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
25% more funds holding
Funds holding: 87 → 109 (+22)
5.35% more ownership
Funds ownership: 69.61% → 74.96% (+5.3%)
7% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 27
2% less call options, than puts
Call options by funds: $453K | Put options by funds: $462K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$29.8M |
| 2 |
Morgan Stanley
New York
|
+$10.3M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
+$6.31M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$3.73M |
| 5 |
RI
RTW Investments
New York
|
+$3.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$15.8M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$5.16M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.85M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$4.79M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.28M |
TSHA Hedge Fund Activity: Q1 2024 in Review
109 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q1 2024, worth a combined $402M — up 75% from $230M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new TSHA positions and 14 closed out — a net gain of 22 holders — while 29 added to existing stakes and 27 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $29.8M. The largest seller was RA Capital Management, cutting an estimated $15.8M.
- 109 institutional investors held Taysha Gene Therapies (TSHA) as of Q1 2024, up from 87 in Q4 2023.
- Funds reported $402M of Taysha Gene Therapies stock for Q1 2024, up 75% quarter-over-quarter.
- 36 funds opened new Taysha Gene Therapies positions in Q1 2024 and 14 closed out, a net change of +22 holders.
- The largest Taysha Gene Therapies buyer in Q1 2024 was Avoro Capital Advisors, an estimated $29.8M added.
- The largest Taysha Gene Therapies seller in Q1 2024 was RA Capital Management, an estimated $15.8M sold.
Based on aggregated 13F filings for Q1 2024.